pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,282 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1816Endpoints1410Fierce Biotech731BioSpace719BioPharma Dive532raps239onclive165fda recalls114
therapy area
allOncology12513Rare Disease3253Immunology2926Cardiology2830Hematology2218Pulmonology2176Vaccines1820
  • Trump touts completion of first round of White House drug pricing deals with Regeneron
    President Trump announced that a pricing agreement with Regeneron marks the final deal of an initial slate of 17 sought by the administration. Under the private arrangement, Regeneron will lower Me…
    STAT · 6mo agoDealNeutral↗ source
  • Trump administration allocates $50 million to psychedelic research and moves to downgrade medical marijuana
    President Trump signed an executive order that earmarks $50 million for research into psychedelics as potential mental‑health treatments and directs the FDA to accelerate their review process. The…
    STAT · 6mo agoRegulatoryNeutral↗ source
← prev
page 92 of 92
next →
fda medwatch113
globenewswire health73
fda press59
Psychiatry & CNS1221
Ophthalmology1079
Endocrinology & Metabolism785
Pain784
Nephrology764
  • Sanofi’s research focus may shift under new CEO Belén Garijo, amid gene therapy advances and telehealth debates
    Sanofi is entering a period of strategic reassessment as Belén Garijo assumes the chief executive role. Observers are watching to see whether the company will adjust its recent emphasis on immunolo…
    STAT · 6mo agoNeutral↗ source
  • CAR-T biotech Kelonia rebounds from cash crises to a $3 billion sale, while drugmakers explore Prescribery partnership
    The latest episode of STAT's "The Readout LOUD" podcast focuses on a dramatic turnaround at a CAR‑T biotech that faced near‑bankruptcy three times before being bought for more than $3 billion. The…
    STAT · 6mo agoPositive↗ source
  • Opinion: Dropping the flu vaccine requirement puts U.S. military readiness at risk
    Since the 1918 pandemic, the military has acknowledged the threat of influenza. Now that’s changing.
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Mouse study links heart's constant beating to a hostile environment for cancer cells
    Heart disease and cancer are leading causes of death, yet tumors are rarely found in the heart, a fact clinicians have noted without clear explanation. Researchers reported in a Science paper that…
    STAT · 6mo agoPositive readoutPositive↗ source
  • Colorado and Virginia lawmakers block attempts to limit drug affordability boards
    Legislators in Colorado and Virginia are pushing back against proposals to curb the authority of state prescription‑drug affordability boards. In Virginia, the General Assembly voted unanimously t…
    STAT · 6mo agoRegulatoryNeutral↗ source